About the Company
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells.
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results
NEWTOWN, Pa., Aug. 15, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),...
NEWTOWN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company...
Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
Company to highlight approaches for studying rigosertib in multiple rare diseases associated with RAS gene at upcoming scientific conference Collaboration with National Cancer Institute (NCI) for evaluation of rigosertib in pediatric rare disease Onconova to host KOL breakfast symposium...
Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid
Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in difficult-to-treat population • The combination may overcome hypomethylating agent resistance; further study in Acute Myeloid Leukemia is...